DE10199020I1 - Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit - Google Patents

Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit

Info

Publication number
DE10199020I1
DE10199020I1 DE2001199020 DE10199020C DE10199020I1 DE 10199020 I1 DE10199020 I1 DE 10199020I1 DE 2001199020 DE2001199020 DE 2001199020 DE 10199020 C DE10199020 C DE 10199020C DE 10199020 I1 DE10199020 I1 DE 10199020I1
Authority
DE
Germany
Prior art keywords
galanthamine
alzheimer
disease
analogues
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE2001199020
Other languages
English (en)
Other versions
DE10199020I2 (de
Inventor
Bonnie Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synaptech Inc
Original Assignee
Synaptech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25227312&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10199020(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synaptech Inc filed Critical Synaptech Inc
Application granted granted Critical
Publication of DE10199020I1 publication Critical patent/DE10199020I1/de
Publication of DE10199020I2 publication Critical patent/DE10199020I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE2001199020 1986-01-15 1987-01-15 Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit. Active DE10199020I2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/819,141 US4663318A (en) 1986-01-15 1986-01-15 Method of treating Alzheimer's disease

Publications (2)

Publication Number Publication Date
DE10199020I1 true DE10199020I1 (de) 2001-05-23
DE10199020I2 DE10199020I2 (de) 2004-05-06

Family

ID=25227312

Family Applications (3)

Application Number Title Priority Date Filing Date
DE8787100461T Expired - Lifetime DE3779149D1 (de) 1986-01-15 1987-01-15 Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE2001199020 Active DE10199020I2 (de) 1986-01-15 1987-01-15 Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE198787100461T Pending DE236684T1 (de) 1986-01-15 1987-01-15 Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE8787100461T Expired - Lifetime DE3779149D1 (de) 1986-01-15 1987-01-15 Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE198787100461T Pending DE236684T1 (de) 1986-01-15 1987-01-15 Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.

Country Status (10)

Country Link
US (1) US4663318A (de)
EP (1) EP0236684B1 (de)
JP (1) JPH08778B2 (de)
AT (1) ATE76294T1 (de)
AU (1) AU593051B2 (de)
DE (3) DE3779149D1 (de)
ES (1) ES2000428T3 (de)
GR (2) GR880300077T1 (de)
LU (1) LU90710I2 (de)
NL (1) NL300140I2 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
ATE411026T1 (de) * 1987-05-04 2008-10-15 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
IT1222395B (it) * 1987-07-30 1990-09-05 Pierrel Spa Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
ATE183084T1 (de) * 1991-05-14 1999-08-15 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) * 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
EP0787115B1 (de) * 1994-10-21 2000-01-05 Sanochemia Pharmazeutika AG VERFAHREN ZUM HERSTELLEN VON DERIVATEN DES 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO[3a,3,2-ef][2]BENZAZEPINS
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU2004242546B2 (en) * 1998-11-23 2008-05-15 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
EP1133230A4 (de) * 1998-11-23 2004-05-26 Bonnie M Davis Dosisformulierungen für acetylcholinesterase-inhibitoren
DE69912311T2 (de) * 1998-12-24 2004-07-29 Janssen Pharmaceutica N.V. Galantamin-zusammensetzung mit gesteuerter freisetzung
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
WO2001054697A1 (en) * 2000-01-28 2001-08-02 Tricia Grose Herbal supplement for cognitive related impairment due to estrogen loss
US6426097B2 (en) 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
PL202463B1 (pl) 2000-03-31 2009-06-30 Sanochemia Pharmazeutika Ag Pochodne galantaminy, sposób ich wytwarzania, środek leczniczy zawierajacy te pochodne, zastosowanie pochodnej galantaminy do wytwarzania środków leczniczych, sposób wytwarzania środków leczniczych oraz sposób oddzielania (+)- i (-)-izomerów
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
CA2310990A1 (en) 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
SI2389937T1 (sl) 2002-06-14 2018-10-30 Toyama Chemical Co., Ltd, Farmacevtska sestava za izboljšanje možganske funkcije
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
TW200418446A (en) * 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
EP1603548A4 (de) * 2003-02-05 2007-10-10 Myriad Genetics Inc Verfahren und zusammensetzung zur behandlung neurodegenerativer erkrankungen
CA2527114A1 (en) * 2003-05-30 2004-12-16 Microbia, Inc. Methods for the protection of memory and cognition
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US20050048543A1 (en) * 2003-07-11 2005-03-03 Jeroen Aerssens CHRNA2 genetic markers associated with galantamine response
EP1651234B1 (de) * 2003-07-25 2007-09-26 F. Hoffmann-La Roche Ag Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
WO2005042762A2 (en) * 2003-10-28 2005-05-12 Genaissance Pharmaceuticals, Inc. Lrpap1 genetic markers associated with galantamine response
BG65658B1 (bg) * 2003-11-13 2009-05-29 "Софарма" Ад Комбиниран лекарствен продукт на основата на галантамин
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US7250258B2 (en) * 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
CA2566204A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
KR20070084455A (ko) * 2004-11-23 2007-08-24 워너-램버트 캄파니 엘엘씨 지질혈증 치료용 ｈｍｇ ｃｏ-ａ 환원효소 억제제로서의7-(2ｈ-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
DE602006016934D1 (de) 2005-04-06 2010-10-28 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
US20070042034A1 (en) * 2005-07-22 2007-02-22 Myriad Genetics, Incorporated High drug load formulations and dosage forms
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
BRPI0718437A2 (pt) 2006-10-27 2013-11-19 Medivation Neurology Inc Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil
PL2271218T3 (pl) * 2008-03-27 2017-10-31 Chase Pharmaceuticals Corp Zastosowanie i kompozycja do leczenie otępienia
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
WO2011034568A1 (en) 2009-09-18 2011-03-24 Chase Pharmaceuticals Corporation Method and composition for treating alzheimer-type dementia
CA2781826A1 (en) 2009-11-26 2011-06-03 Usv Limited Controlled release pharmaceutical compositions of galantamine
EP2533645B1 (de) 2010-02-09 2016-07-27 The Johns Hopkins University Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
EP2892514A4 (de) 2012-09-05 2016-04-13 Chase Pharmaceuticals Corp Neuroprotektive anticholinergische zusammensetzung und verfahren
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
BG66818B1 (bg) 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (de) 2013-03-15 2021-05-05 Agenebio, Inc. Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
US10357486B2 (en) 2013-08-16 2019-07-23 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Also Published As

Publication number Publication date
GR3005447T3 (de) 1993-05-24
ATE76294T1 (de) 1992-06-15
US4663318A (en) 1987-05-05
JPS62215527A (ja) 1987-09-22
NL300140I1 (nl) 2004-02-02
ES2000428A4 (es) 1988-03-01
GR880300077T1 (en) 1988-10-21
DE236684T1 (de) 1988-04-28
ES2000428T3 (es) 1993-10-01
ES2000428T9 (es) 2013-08-14
JPH08778B2 (ja) 1996-01-10
NL300140I2 (nl) 2004-04-01
AU6760987A (en) 1987-07-16
LU90710I2 (fr) 2001-03-05
EP0236684A2 (de) 1987-09-16
EP0236684B1 (de) 1992-05-20
DE10199020I2 (de) 2004-05-06
DE3779149D1 (de) 1992-06-25
EP0236684A3 (en) 1988-12-14
AU593051B2 (en) 1990-02-01

Similar Documents

Publication Publication Date Title
ATE76294T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE3779346D1 (de) Zusammensetzung zur behandlung der haut.
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
DE3882775T2 (de) Zusammensetzung zur Behandlung von parodontaler Krankheit.
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE68912913D1 (de) Vorrichtung zur elektrolytischen Behandlung von metallischen Gegenständen.
DE68907569T2 (de) Mittel zur Behandlung oder Vorbeugung von Aids.
DE69300037T2 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE68913779D1 (de) D-Amidase und Verfahren zur Herstellung von D-alpha-Alanin und/oder L-alpha-Alaninamid.
DE68908445T2 (de) Mittel zur Behandlung von Lebererkrankungen.
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE69011065D1 (de) Verfahren zur Behandlung von Nickel-Magnesium-Silikaterzen.
DE68906028T2 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE79529T1 (de) Vorrichtung zur stimulation von gliedversteifungen.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
FI871737A0 (fi) Kraftanlaeggning med foerbraenning i en fluidiserad baedd.
ATE95061T1 (de) Schmiermittelzubereitung zur behandlung von rheuma.
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.
ATE59106T1 (de) Anordnung zur behandlung von bildern.
ATE91886T1 (de) Praeparat zur behandlung von erektionsstoerungen.
DE3770945D1 (de) Vorrichtung zur behandlung von luftschiffen.